For adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), the steepest barriers to high-quality care ...

The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

The report charts major advances in precision oncology and immunotherapy but also reveals stagnant survival for several ...

The parents of a 15-month-old girl who spent months without a diagnosis finally learned their daughter had a rare subtype of ...

A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...

A chemotherapy-free-based regimen of the TKI ponatinib combined with targeted immunotherapy showed significant benefits in ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.